Contagion Editorial Team

In this month's column, a federal district court struck down the

Gilead Sciences will receive FDA review for its investigational bictegravir/lenacapavir (BIC/LEN) single-tablet HIV regimen, with a decision expected by late summer.

This week, read a clinician's insights on a new FDA-approved HIV therapy, the CDC cancels publication of a COVID-19 vaccine study, moving up hepatitis C cure timelines, and more.

Doravirine/islatravir (Idvynso), is a non-INSTI, tenofovir-free alternative for virologically suppressed adults, with efficacy, safety, and potential benefits for aging populations managing complex treatment needs. Amy Colson, MD, MPH, offers some insights about the phase 3 trial and how clinicians may want to consider its use for patients.

Jonathan Batchelder, PhD, provides insights around his research that showed that Staphylococcus aureus can survive fluoroquinolone treatment under nutrient-limited conditions even without key DNA repair proteins, pointing to alternative survival pathways and implications for future therapies.

Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.

The agency’s acting director took the unusual step of withholding the publication of the study findings in the Morbidity and Mortality Weekly Report, which showed the vaccine was protective against hospitalization and emergency department visits.

Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.

The federal agency has given the nod to doravirine/islatravir (Idvynso), a once-daily, 2-drug HIV treatment that demonstrated noninferior efficacy to standard 3-drug regimens in phase 3 trials, expanding options for adults with virological suppression.

Our short survey underscores the critical role of audience feedback in shaping more relevant, impactful infectious disease coverage.

In the third part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he says insurance restrictions are forcing people with C diff to endure inferior treatments and repeated infections raising both human suffering and long-term healthcare costs.

A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.

AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.

New research shows that antiretroviral therapy can reduce HIV-related accelerated biological aging by nearly 4 years, highlighting the critical importance of early and sustained treatment.

This week, read about AI and antibiotic development, an innovative hepatitis C program to get postpartum mothers tested and treated sooner, on World Liver Day a nurse talks about her personal story and how she advocate for better education around this vital organ, and more.

A large real-world study from the UK Health Security Agency presented at ESCMID Global 2026 finds that maternal RSV vaccination given at least two weeks before birth cuts infant hospitalizations by more than 80%.

Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.

Madeline McCrary, MD, explains her institution’s program as a novel way to get new mothers diagnosed and given their full-course of treatment when they are still in the hospital.

In the second episode of this short series, Akhila Kosaraju, MD, talks about how Phare Bio and Basilea Pharmaceuticals are partnering to develop antimicrobials taking them from AI molecules to clinical trials.

A new study shows that strain-level surveillance of Staphylococcus aureus in NICUs can identify hidden transmission pathways and enable targeted interventions to reduce serious infections in vulnerable newborns.

Akhila Kosaraju, MD, provides insights around how AI is moving towards an accelerated pace of antimicrobial development in hopes of getting molecules into clinical trials and approved much faster than the current paradigm.

Shionogi has been awarded a major US government contract to scale domestic manufacturing and expand the use of its antibiotic cefiderocol to combat antimicrobial resistance and high-priority biothreat pathogens.

A large cluster-randomized trial in Singapore found that releasing sterile male Wolbachia-infected mosquitoes greatly reduced dengue infections by suppressing local mosquito populations.

The inaugural MAD-ID and SIDP 2026 meeting aims to provide new infectious diseases education offerings, dynamic speakers, and strong networking opportunities for younger clinicians. SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, offers some insights around the upcoming event.

Early adoption of genomic surveillance and rigorous infection prevention protocols has enabled one health system to prevent in-hospital outbreaks of Candida auris despite rising cases nationwide. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) provides insights on how his institution is handling testing for this problematic fungal infection.

This week, read about omadacycline as an oral treatment option for Mycobacterium abscessus pulmonary disease, combining immunotherapy with antifungals for fungal infections, this year's Peggy Lillis Foundation's C diff meeting, and more.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, offers some insights on the disease burden, and an overview of his company’s pipeline around developing a therapy for this STI.

The organization announced this year's event, which aims to bring together stakeholders in Washington, DC, to advance awareness, policy, and patient-centered solutions for Clostridioides difficile infection.

Martin Gartland, PhD, discusses early data on the investigational therapy, VH184, including the potential for long-acting treatment and looking to address emerging drug resistance challenges.

This week, read about a new COVID variant, the test and treat paradigm model for hepatitis C, and a mission around bringing Americans with Ebola back to the US.